This paper presents views on the current status of (inorganic) 
since 1991 to stu isse relatd to arsenic risk aessment and has held worikhops and in nial o rnces on arsenic The topic of this paper is made time by cunt sdctific in in exure to and aders health effec of arsenic in the United States and pasage of the Safe Drinin Waer Act Amendments of 1996, which has provisions for a reseasch program on arsenic and a schedule mandatig the EPA to revise the maximum contaminant level ofarsec in drinking water by the In selected regions of the world, long-term ingestion of arsenic at relatively high concentrations in drinking water has been associated with disorders of the skin ranging from hyperpigmentation or hypopigmentation and hyperkeratosis to various skin cancers; with cancers of the bladder, liver, lung, kidney, colon, and other internal organs; with peripheral vascular disorder that may include blackfoot disease; and with other confirmed or suspected adverse effects including diabetes, ischemic heart disease, reproductive effects, and impairment of liver function (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Observed toxicity has largely been associated with inorganic arsenic, which is the focus of this paper. (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Remediation has reduced arsenic concentrations in water used for duinking or irrigation in some locations but not in others. In India and Bangladesh, for example, hundreds of thousands of persons are currendy exposed to highly toxic levels of arsenic in water from tube wells used fior drinking and irrigation (18) (19) (20) (21) .
In the United States, total nonoccupational exposure to irnorganic arsenic (hereafter called arsenic) from all routes is primarily by ingesticin of water and food (28) (29) (30) (31) (32) (33) (34) (1) notes that "experimental studies with rats, chicks, minipigs, and goats demonstrate the plausibility that arsenic, at least in inorganic form, is an essential nutrient," but adds that nutritional essentiality for humans has not been established [also see Uthus (39, 40) ].
Aside from whether trace amounts of arsenic may be beneficial, some mechanistic studies on metabolism, genotoxicity, and other factors suggest the dose-response relationship may be nonlinear, i.e., there may either be a threshold (dose level below which there is no effect) or the dose is relatively less effective at low levels. As will be discussed, however, consensus is lacking on the nonlinearity issue, and even if the concept is correct, there is a limited basis for incorporating it into dose-response assessment at the individual or population level. (Fig. 1) , the MCL for a fixedlifetime risk would be higher and less (possibly much less) costly to implement. That the MCL should be correctly set to protect public health, whatever the appropriate MCL level may be, is not at issue. Our concern on this point lies with the default assumption used by the EPA and whether it is appropriate for arsenic.
Some evidence suggests that the incidence of health effects may drop more than proportionally to dose, making the correct dose-response shape resemble the threshold or nonlinear curves in Figure 1 . The evidence indudes metabolic studies in animals (51) , metabolic studies in human populations consuming drinking water with high levels of arsenic (24, clinical studies of a small number of human volunteers (54, and genotoxicological studies of the arsenic dose-response relationship (53) . Some recent analyses of epidemiological data also add to the uncertainty about the EPA's linear-at-low-dose assumption for arsenic (54, 55) . Conflicting evidence has led to contention, however, supporting the need for further research. For example, Hopenhayn-Rich et al. (56) conduded that human studies do not support a methylation threshold hypothesis. They analyzed data from studies that measured urinary inorganic arsenic and the metabolites monomethylarsonic acid (MMA) and dimethylarsenic acid (DMA) in different populations; they found that, on average, 20-25% of inorganic arsenic remains unmethylated regardless of the exposure level. Further discussion of these issues has appeared elsewhere (57) (58) (59) (60) (61) (62) (63) .
These studies may be contrasted with equally recent studies from Mexico that do show an impact of arsenic dose on methylation, particularly when considered in terms of the DMA:MMA ratio (64, 65) .
If a practical threshold (as illustrated by the nonlinear curve in Fig. 1 ) for chronic arsenic toxicity does exist, the public health benefit from large expenditures to reduce arsenic levels in water and soil will be small, perhaps negligible. The magnitude of these expenditures should be a strong incentive to discover whether such a practical threshold is evident in the human data. Because of the need to improve the quality of the measurements of both arsenic exposure levels and health effects in the existing studies, such a determination will require additional research.
Under a directive from Congress, the National Academy of Sciences (NAS) recendy reviewed the EPA's risk assessment methodology for environmental carcinogens (47). The NAS supported the EPA's use of default assumptions (induding those leading to a dose response that is linear at low exposure, as in the linear and linearquadratic curves of Fig. 1 (72) .
Several physiologically based pharmacokinetic (PBPK) models are being developed that relate intake of inorganic arsenic to concentrations in tissue and, along with metabolites MMA and DMA, in urine (73) (74) (75) (76) . Recent observations from humans exposed to relatively high levels ofarsenic in drinking water indicate a need to determine ratios of inorganic arsenic, MMA, and DMA as measured in urine, rather than just the inorganic arsenic exposure, to evaluate the saturation of metabolic detoxification processes (22, 77) . It is important to recognize that saturation of arsenic metabolism does not mean that no detoxification of arsenic occurs above a certain exposure level, but that the relative effectiveness is decreased above that exposure level.
Toxicological studies, primarily in animals, demonstrate that nutritional deficiencies can result in impaired arsenic metabolism (78) . Thus, nutritional deficiencies may contribute to the high incidence of arsenicinduced human health effects in India and Taiwan (13) (14) (15) For example, the Tseng study (5, 6 ) used in the 1988 EPA risk assessment collected skin cancer data on individuals, but relied on a previous study for exposure data on wells tested for arsenic concentrations. Participants were identified with a village but not with the specific well within the village used for drinking water. In some villages, only one well was tested, and in those with multiple tests, the outcomes covered a wide range. The health effects were first grouped by village, with the average well concentration used as the exposure index for the whole village. The health effects data were then combined across villages with an exposure index in the same interval, 0-300 pg/l, 300-600 jig/l, or >600 pg/l. The well tests and average value for each village were not reported in the published study (5) . An attempt to reconstruct the exposure data by village in the Tseng study found that villages categorized in the 0-300 pg/l group probably contained some wells with concentrations as high as 770 pg/l (79 Some health endpoints may not have as extended a latency period as cancer, or the effects of exposure duration may be unknown, e.g., cardiovascular disease or adverse pregnancy outcome. Thus, the health endpoints that may be studied in a location, the existence of medical records and arsenic exposure histories, and the type of epidemiological study (case-control, retrospective cohort, prevalence, etc.) that might be conducted are interrelated, making it necessary to assess the potential for each candidate study location separately. There are, of course, additional issues related to cooperation and participation by the host country: existence of personnel, facilities, and other resources and the cost and duration to complete a study. The AWWARF is currently funding a project to study the feasibility of conducting epidemiological studies on arsenic, following research recommendations from a workshop held in 1995 (70) .
Although previous epidemiological studies in the United States have not found evidence of excess cancer associated with arsenic exposure, further investigations are under way that indude endpoints such as cardiovascular disease. However, the small number of people exposed to relatively high arsenic levels in the United States and the limited range of exposure make the United States an unlikely location for a dose-response study. Additionally, the U.S. population is relatively mobile, making it difficult to estimate arsenic exposure over several decades of a lifetime. By contrast, some populations with high arsenic exposure outside the United States are relatively stationary, thus providing a better opportunity to assess lifetime exposure. Also, exposed populations are much larger than in the United States and exhibit a much wider range of exposure over which to observe the shape of the dose-response relationship. Epidemiological study designs to address potential high bladder cancer risks from arsenic in drinking water are discussed by Vahter and Marafante (78) .
Combining epidemiological with mechanistic studies in highly exposed populations. Biomarkers are indicators in biological media (e.g., urine, blood) that can be used to measure either exposure or an effect of exposure. A useful biomarker of recent exposure to arsenic is inorganic arsenic Superfund guidance requires consideration of soil screening levels (SSLs), which are chemical concentrations in soil below which there is no concern for human health risk (41) . An exceedance of the SSL does not indicate the automatic need for remedial action at a Superfund site, but rather the need for further analysis. For carcinogens, the EPA sets SSLs at the soil concentration associated with a 10-6 risk. In the case of arsenic, the SSL is 0.4 mg/kg, which is below the geometric mean arsenic concentration of 5 
